pharma · Facioscapulohumeral Muscular Dystrophy (FSHD) · Facioscapulohumeral Muscular Dystrophy 1 (FSHD1) · FULC
Fulcrum Therapeutics
Fulcrum Therapeutics is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker FULC. Primary therapeutic focus areas include Facioscapulohumeral Muscular Dystrophy (FSHD), Facioscapulohumer
26 Landsdowne St, Cambridge, Massachusetts 02139, US HQ
2016 Founded
73 Employees
Public company Type
FULC · NYSE Ticker
Company details
- Status
- Public
- HQ
- 26 Landsdowne St, Cambridge, Massachusetts 02139, US
- Founded
- 2016
- Employees
- 73
- Programs
- 12
- Drugs
- 8
- Patents
- 11
ACE393
Phase 2 · mab · Campylobacter Infection
ACE393 for Campylobacter Infection is a Phase 2 program (mab) at Fulcrum Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code ACE393-103
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Fulcrum Therapeutics
- Phase
- Phase 2
- Modality
- mab
- Indication
- Campylobacter Infection
- Status
- active
- Trials
- 1